Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon...

Full description

Bibliographic Details
Published in:	Molecular Metabolism
Main Authors:	Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K. Olsen, Diego Perez-Tilve, Richard D. DiMarchi, Brian Finan
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Subjects:	Obesity Pharmacology Triagonist Glucagon GLP-1 GIP
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877822001028

Similar Items

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
by: Brian Finan, et al.
Published: (2025-06-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
by: Qiyuan Keith Liu
Published: (2024-07-01)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
by: Bo Ahrén
Published: (2023-02-01)

Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice
by: Seun Akindehin, et al.
Published: (2024-05-01)

Glucose-dependent insulinotropic polypeptide (GIP)
by: Timo D. Müller, et al.
Published: (2025-05-01)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
by: Tiago Morais, et al.
Published: (2023-04-01)

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
by: Leigh Perreault, et al.
Published: (2024-06-01)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
by: Tomislav Bulum
Published: (2022-10-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
by: Shahini Winson Gnanathayalan, et al.
Published: (2024-01-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
by: Velimir Altabas, et al.
Published: (2025-06-01)

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms
by: Othman Al Musaimi
Published: (2024-02-01)

G protein-coupled receptors and obesity
by: Alessandro Pocai
Published: (2023-12-01)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022-05-01)

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
by: Sandra Christensen, et al.
Published: (2024-09-01)

Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
by: Bin Yang, et al.
Published: (2022-12-01)

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity
by: Malwina Jędrysik, et al.
Published: (2024-01-01)

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
by: Stephan Sachs, et al.
Published: (2023-08-01)

A Comprehensive Review on the Pharmacokinetics and Drug&minus;Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
by: Min JS, et al.
Published: (2025-04-01)

Glucose metabolism and incretins level in morbidly obese patients and in patients after biliopancreatic diversion performed for morbid obesity
Published: (2014-03-01)

Effect of high intakes of protein-only and carbohydrate-only on plasma metabolites and hormones, in addition to nitrogen excretion
by: Matthieu Clauss, et al.
Published: (2025-08-01)

Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
by: Ola Lindgren, et al.
Published: (2020-07-01)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
by: Bastin M, et al.
Published: (2019-09-01)

Stimulating intestinal GIP release reduces food intake and body weight in mice
by: Jo E. Lewis, et al.
Published: (2024-06-01)

Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides
by: Crawford Currie, et al.
Published: (2024-10-01)

The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD
by: Cheng Li, et al.
Published: (2020-03-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Qian Zhou, et al.
Published: (2023-10-01)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity
by: Svjatoslavs Kistkins, et al.
Published: (2024-05-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
by: Isabella Zaffina, et al.
Published: (2023-02-01)

Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US
by: Steven D Pearson, et al.
Published: (2025-01-01)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
by: Fatemeh Taktaz, et al.
Published: (2024-07-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024-06-01)

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
by: Ferenc Sztanek, et al.
Published: (2024-06-01)